KR102096557B1 - 통증 치료용 약학 조성물 - Google Patents

통증 치료용 약학 조성물 Download PDF

Info

Publication number
KR102096557B1
KR102096557B1 KR1020180057362A KR20180057362A KR102096557B1 KR 102096557 B1 KR102096557 B1 KR 102096557B1 KR 1020180057362 A KR1020180057362 A KR 1020180057362A KR 20180057362 A KR20180057362 A KR 20180057362A KR 102096557 B1 KR102096557 B1 KR 102096557B1
Authority
KR
South Korea
Prior art keywords
morphine
pain
amino
mice
opioid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020180057362A
Other languages
English (en)
Korean (ko)
Other versions
KR20180127248A (ko
Inventor
민 주오
Original Assignee
포에버 치어 인터내셔널 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 포에버 치어 인터내셔널 리미티드 filed Critical 포에버 치어 인터내셔널 리미티드
Publication of KR20180127248A publication Critical patent/KR20180127248A/ko
Application granted granted Critical
Publication of KR102096557B1 publication Critical patent/KR102096557B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020180057362A 2017-05-20 2018-05-18 통증 치료용 약학 조성물 Active KR102096557B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JPJP-P-2017-100431 2017-05-20
JP2017100431A JP7332841B2 (ja) 2017-05-20 2017-05-20 疼痛を治療するための薬用組成物

Publications (2)

Publication Number Publication Date
KR20180127248A KR20180127248A (ko) 2018-11-28
KR102096557B1 true KR102096557B1 (ko) 2020-04-03

Family

ID=62200214

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020180057362A Active KR102096557B1 (ko) 2017-05-20 2018-05-18 통증 치료용 약학 조성물

Country Status (12)

Country Link
US (2) US20180333420A1 (enExample)
EP (1) EP3403674B1 (enExample)
JP (1) JP7332841B2 (enExample)
KR (1) KR102096557B1 (enExample)
CN (1) CN108743589B (enExample)
AU (1) AU2018203501B2 (enExample)
CA (1) CA3005375C (enExample)
DK (1) DK3403674T3 (enExample)
ES (1) ES2886855T3 (enExample)
IL (1) IL259442A (enExample)
TW (1) TWI729290B (enExample)
ZA (1) ZA201803320B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114984020B (zh) * 2022-01-20 2024-08-30 永展控股有限公司 腺苷酸环化酶抑制剂在制备用于治疗癫痫及其相关疾病的药物中的用途
CN114931561B (zh) * 2022-05-25 2024-02-02 青岛永展医药科技有限公司 一种治疗慢性痛的胶囊组合物及其制备方法
CN115990167A (zh) * 2023-02-17 2023-04-21 永展控股有限公司 腺苷酸环化酶抑制剂nb001在制备治疗偏头痛和焦虑药物中的用途
CN115998745B (zh) * 2023-02-17 2024-05-14 永展控股有限公司 腺苷酸环化酶抑制剂nb001在制备治疗帕金森氏病疼痛和焦虑药物中的用途
CN118526502A (zh) * 2024-07-24 2024-08-23 浙江永展医药科技有限公司 腺苷酸环化酶抑制剂用于制备治疗围手术期疼痛药物的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007041863A1 (en) * 2005-10-14 2007-04-19 Min Zhuo Method for treating neuronal and non-neuronal pain
US20110098295A1 (en) * 2009-10-22 2011-04-28 Min Zhuo Methods of treating anxiety, itching and psychiatric disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6902336B2 (ja) * 2016-08-01 2021-07-14 永展国際有限公司Ｆｏｒｅｖｅｒ Ｃｈｅｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ ５−［２−［（６−アミノ）−９ｈ−プリン−９−イル］エチルアミノ］−１−ペンタノール多結晶体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007041863A1 (en) * 2005-10-14 2007-04-19 Min Zhuo Method for treating neuronal and non-neuronal pain
US20110098295A1 (en) * 2009-10-22 2011-04-28 Min Zhuo Methods of treating anxiety, itching and psychiatric disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
H. Wang 외. Science Translational Medicine, Vol. 3(65), 2011, pp. 65
Ming-ing Zhang 외. Molecular Brain, Vol. 7(1), 2014, pp. 47

Also Published As

Publication number Publication date
JP2019052094A (ja) 2019-04-04
KR20180127248A (ko) 2018-11-28
TWI729290B (zh) 2021-06-01
ES2886855T3 (es) 2021-12-21
TW201900173A (zh) 2019-01-01
AU2018203501B2 (en) 2019-11-21
EP3403674B1 (en) 2021-06-30
IL259442A (en) 2018-06-28
CN108743589A (zh) 2018-11-06
DK3403674T3 (da) 2021-08-30
JP7332841B2 (ja) 2023-08-24
CN108743589B (zh) 2021-05-14
US20200268766A1 (en) 2020-08-27
US20180333420A1 (en) 2018-11-22
EP3403674A1 (en) 2018-11-21
CA3005375C (en) 2020-12-08
AU2018203501A1 (en) 2018-12-06
ZA201803320B (en) 2019-04-24
CA3005375A1 (en) 2018-11-20
US11541060B2 (en) 2023-01-03

Similar Documents

Publication Publication Date Title
KR102096557B1 (ko) 통증 치료용 약학 조성물
EP2081431B1 (en) Organic compounds
EP3509589B1 (en) Novel uses
EP2089029B1 (en) Pak inhibitors for use in treating neurodevelopmental disorders
JP2010116412A (ja) 精神分裂病を治療するための方法および組成物
CN112955150A (zh) 与nad+或nad+前体组合的sarm1抑制剂
EP4125884A1 (en) Eif4a inhibitor combinations
JP2017502059A (ja) 製剤および医薬組成物
KR20200051585A (ko) 펜타시클릭 화합물
WO2002076990A1 (en) Thiazolopyrimidine derivatives and use thereof as antagonists of the cx3 cr1 receptor
AU2005277154A1 (en) T type calcium channel blockers and the treatment of diseases
MX2007002169A (es) Inhibidores de cdk de purina y pirimidina y su uso para el tratamiento de enfermedades inmunes.
EP3484474A1 (en) Calmodulin inhibitors, chk2 inhibitors and rsk inhibitors for the treatment of ribosomal disorders and ribosomapathies
US20090169540A1 (en) Use Of An Antagonist Of Epac For Treating Human Cardiac Hypertrophy
EP2074998B1 (en) Use of cyclic bioisosteres of purine system derivatives for the treatment of diseases caused by disorders of nitrergic and dopaminergic systems
KR102352624B1 (ko) LRRK2 (Leucine Rich Repeat Kinase 2) 키나제 억제제로서의 피리도피리미딘 유도체 화합물
JP7692128B2 (ja) 新規化合物及び医薬組成物
HK1248679B (en) Hydantoin containing deoxyuridine triphosphatase inhibitors
HK1248679A1 (en) Hydantoin containing deoxyuridine triphosphatase inhibitors

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20180518

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190617

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20200224

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200327

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200330

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20230119

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20240111

Start annual number: 5

End annual number: 5